 The FDA has lifted the clinical hold on KalVista Pharmaceuticals Incs NASDAQ: KALV Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema HAE. Related Content: KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824. 